Haemonetics to Acquire Attune Medical

Haemonetics Corporation Acquires OpSens Inc.

December 12, 2023

Medical Devices

Haemonetics Corporation completed its acquisition of OpSens Inc. in an all-cash transaction for CAD $2.90 per share, representing a fully diluted equity value of approximately USD $255 million. The deal expands Haemonetics' hospital/interventional cardiology portfolio with OpSens' fiber-optic sensor technology (including the SavvyWire and OptoWire); OpSens will be delisted and Haemonetics expects OpSens to contribute $55–$65 million in revenue in fiscal 2025.

Haemonetics Acquires Cardiva Medical

January 20, 2021

Medical Devices

Haemonetics Corporation agreed to acquire Cardiva Medical, Inc., a privately-held maker of vascular closure systems based in Santa Clara, California, for $475 million upfront and up to $35 million in contingent consideration. The acquisition expands Haemonetics' hospital portfolio and its presence in the interventional cardiology and electrophysiology markets and is expected to be accretive to revenue growth.

Haemonetics Acquires Vivasure Medical

January 11, 2026

Medical Devices

Haemonetics Corporation has acquired Galway-based Vivasure Medical in a transaction valued at up to €185 million, consisting of an upfront €100 million payment plus up to €85 million in contingent milestone payments. The acquisition adds Vivasure's PerQseal Elite fully bioabsorbable vascular closure system to Haemonetics' large-bore closure portfolio; Vivasure has CE Mark approvals and has submitted a PMA to the U.S. FDA.

Integration Health Acquires ECMO Advantage

September 18, 2025

Healthcare Services

Integration Health has acquired ECMO Advantage, combining two leading ECMO, perfusion, and transplant support providers to create a unified national platform. The combined organization will serve over 55 hospitals across 22 states, expanding specialized clinical staffing, program development, transport, and education services for ECMO and perfusion care.

Esperion Therapeutics to Acquire Corstasis Therapeutics

March 5, 2026

Biotechnology

Esperion Therapeutics announced it has entered into a definitive agreement to acquire Corstasis Therapeutics for an upfront cash payment of $75 million, with potential milestone payments of up to $180 million. The deal is expected to add Enbumyst (bumetanide nasal spray) to Esperion’s cardiovascular portfolio, leveraging its commercial infrastructure to expand its cardiovascular franchise.

AMETEK Acquires Paragon Medical from American Securities for ~$1.9B

October 31, 2023

Medical Devices

AMETEK, Inc. has agreed to acquire Paragon Medical, a Pierceton, Indiana-based contract manufacturer of medical components and instruments, from private equity firm American Securities in an all-cash transaction valued at approximately $1.9 billion. The deal advances AMETEK’s capabilities and footprint in medical device manufacturing and is subject to customary closing conditions and regulatory approvals.